# Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

> **NCT05267626** · PHASE1,PHASE2 · RECRUITING · sponsor: **Aulos Bioscience, Inc.** · enrollment: 159 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Cancer
- Cutaneous Melanoma
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** AU-007
- **DRUG:** Aldesleukin
- **DRUG:** Avelumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05267626
- **Lead sponsor:** Aulos Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-04
- **Primary completion:** 2026-06-12
- **Final completion:** 2026-06-12
- **Target enrollment:** 159 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267626, "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05267626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*